PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-36.86%
Negative ROE indicates either losses or negative equity – a major Benjamin Graham warning. Confirm if leverage or poor profitability is the cause.
80.34%
ROA above 20% – Exceptional asset efficiency. Peter Lynch would check if this is sustained by a durable growth strategy.
395.15%
ROCE above 25% – Excellent capital efficiency. Warren Buffett would verify if this stems from a sustainable competitive advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.